science and innovation | January 09, 2026

Dr. Sumanta Pal, MD – Duarte, CA

Sumanta (Monty) Kumar Pal, M.D., is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program.

Dr. Pal entered college at the age of 13 and began medical school at University of California, Los Angeles at the age of 17. After completing his residency training at University of California, Los Angeles, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he remains on faculty since 2009.

Over that span of time, he has published more than 450 peer-reviewed articles that have been featured in prominent journals including The Lancet, Journal of Clinical Oncology, Lancet Oncology, Cancer Cell, and European Urology.

Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the west coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for our currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers, with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets.